Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Final analysis of the prospective, observational REFINE study

被引：1

作者：

Kim, Y. J. ^{[1
]}

Kurosaki, M. ^{[2
]}

Numata, K. ^{[3
]}

Lim, H. Y. ^{[4
]}

Ikeda, M. ^{[5
]}

Kudo, M. ^{[6
]}

Huang, Y-H. ^{[7
]}

Shao, G. ^{[8
]}

Kato, N. ^{[9
]}

Kim, D-Y. ^{[10
]}

Cho, S-B. ^{[11
]}

Hsu, C-H. ^{[12
]}

Lin, S-M. ^{[13
]}

Jeng, L-B. ^{[14
]}

Kuo, K-K. ^{[15
]}

Mao, Y. ^{[16
]}

Chewaskulyong, B. ^{[17
]}

Khan, J. ^{[18
]}

Ozgurdal, K. ^{[19
]}

Qin, S. ^{[20
]}

机构：

[1] Seoul Natl Univ Hosp, Liver Canc Ctr, Seoul, South Korea

[2] Musashino Red Cross Hosp, Dept Gastroenterol & Hepatol, Tokyo, Japan

[3] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan

[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

[5] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[6] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[7] Taipei Vet Gen Hosp, Div Gastrotenterol & Hepatol, Taipei, Taiwan

[8] Zhejiang Canc Hosp, Canc Res Inst, Dept Intervent, Hangzhou, Peoples R China

[9] Chiba Univ Hosp, Dept Gastroenterol, Chiba, Japan

[10] Severance Hosp, Dept Internal Med, Seoul, South Korea

[11] Chonnam Natl Univ, Hwasun Hosp, Hepatol Internal Med, Hwasun, South Korea

[12] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan

[13] Linkou Chang Gung Mem Hosp, Chang Gung Med Fdn, Dept Gastroenterol & Hepatol, Taoyuan, Taiwan

[14] China Med Univ Hosp, Dept Surg, Taichung, Taiwan

[15] Kaohsiung Med Univ, Chung Ho Mem Hosp, Div Gen & Digest Surg, Kaohsiung, Taiwan

[16] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Dept Liver Surg, Beijing, Peoples R China

[17] Maharaj Nakorn Chiang Mai Hosp, Fac Med, Chiang Mai, Thailand

[18] Bayer PLC, Oncol, Reading, Berks, England

[19] Bayer Consumer Care AG, Med Dept, Basel, Switzerland

[20] Nanjing Bayi Hosp, Chinese Peoples Liberat Army Canc Ctr, Nanjing, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.10.109

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

73MO

引用

页码：S1459 / S1460

页数：3

共 50 条

[1] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study
Kaseb, Ahmed Omar
Cabrera, Roniel
Iyer, Renuka
Parikh, Neehar
Kalman, Richard
Ozgurdal, Kirhan
Khan, Javeed
Babajanyan, Svetlana
Finn, Richard S.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Lim, H. Y.
Kim, Y. J.
Huang, Y-H.
Shao, G.
Kim, D. Y.
Cho, S. B.
Hsu, C-H.
Lin, S-M.
Jeng, L-B.
Kuo, K-K.
Mao, Y.
Zhu, K.
Hong, Y. M.
Lee, H. C.
Ryoo, B-Y.
Niu, Z.
Wu, L.
Fiala-Buskies, S.
Kapur, S.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S1306 - S1307
[3] Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Asia: Interim results from the observational REFINE study
Lim, H. Y.
Kim, Y. J.
Huang, Y-H.
Shao, G.
Kim, D. Y.
Cho, S. B.
Hsu, C-H.
Lin, S-M.
Jeng, L-B.
Kuo, K-K.
Mao, Y.
Zhu, K.
Hong, Y. M.
Lee, H. C.
Ryoo, B-Y.
Niu, Z.
Wu, L.
Fiala-Buskies, S.
Kapur, S.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S699 - S699
[4] Real-world dosing of regorafenib in patients with unresectable hepatocellular carcinoma (uHCC): Final analysis of the prospective, observational REFINE study.
Finn, Richard S.
Merle, Philippe
Ikeda, Masafumi
Klumpen, Heinz-Josef
Masi, Gianluca
Granito, Alessandro
Lim, Ho Yeong
Kudo, Masatoshi
Qin, Shukui
Gerolami, Rene
Huang, Yi-Hsiang
Kim, Do Young
Pinter, Matthias
Kato, Naoya
Kurosaki, Masayuki
Numata, Kazushi
Khan, Javeed
Ozgurdal, Kirhan
Kim, Yoon Jun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 518 - 518
[5] Regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world (RW) practice: Final analysis of the prospective, observational REFINE study by prior liver transplantation (PLT)
Pinter, M.
Kim, Y. J.
Merle, P.
Finn, R. S.
Khan, J.
Ozgurdal, K.
Qin, S.
ANNALS OF ONCOLOGY, 2023, 34 : S611 - S611
[6] Real-world dosing of regorafenib (REG) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Interim analysis (IA) of the observational REFINE study
Merle, P.
Lim, H. Y.
Finn, R. S.
Ikeda, M.
Kudo, M.
Frenette, C.
Masi, G.
Kim, Y. J.
Gerolami, R.
Kurosaki, M.
Numata, K.
Klumpen, H-J.
Zebger-Gong, H.
Fiala-Buskies, S.
Ozgurdal, K.
Qin, S.
ANNALS OF ONCOLOGY, 2020, 31 : S699 - S700
[7] Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Interim analysis of the prospective, observational REFINE trial
Lim, Ho Yeong
Merle, Philippe
Finn, Richard S.
Frenette, Catherine
Masi, Gianluca
Ikeda, Masafumi
Zebger-Gong, Hong
Fiala-Buskies, Sabine
Ozgurdal, Kirhan
Kudo, Masatoshi
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[8] Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study
Finn, Richard S.
Kudo, Masatoshi
Klumpen, Heinz-Josef
Lim, Ho Yeong
Merle, Philippe
Ikeda, Masafumi
Masi, Gianluca
Frenette, Catherine T.
Kim, Yoon Jun
Gerolami, Rene
Kurosaki, Masayuki
Numata, Kazushi
Pisarenko, Julia
Ozgurdal, Kirhan
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[9] Analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) and Child-Pugh (CP)-B liver function treated with regorafenib in routine clinical practice in the observational REFINE study
Kim, Yoon Jun
Merle, Philippe
Finn, Richard S.
Kudo, Masatoshi
Klumpen, Heinz-Josef
Lim, Ho Yeong
Pinter, Matthias
Babajanyan, Svetlana
Khan, Javeed
Awan, Maria
Ozgurdal, Kirhan
Qin, Shukui
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 452 - 452
[10] Contemporary real-world evidence in unresectable HCC (uHCC) patients treated with regorafenib in Taiwan: Interim results from the observational REFINE study
Lin, Shi-Ming
Hsu, Chih-Hung
Jeng, Long-Bin
Lin, Yih-Jyh
Lee, Ming-Yang
Lee, Teng-Yu
Huang, Yi-Hsiang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)

← 1 2 3 4 5 →